Provided by Tiger Trade Technology Pte. Ltd.

Clearmind Medicine, Inc.

0.7150
-0.0008-0.11%
Post-market: 0.72990.0149+2.08%19:49 EDT
Volume:100.92K
Turnover:73.02K
Market Cap:2.41M
PE:-0.05
High:0.7400
Open:0.7400
Low:0.7055
Close:0.7158
52wk High:480.00
52wk Low:0.7055
Shares:3.37M
Float Shares:3.37M
Volume Ratio:0.98
T/O Rate:3.00%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-14.8013
EPS(LYR):-303.4772
ROE:-106.98%
ROA:-53.08%
PB:0.19
PE(LYR):0.00

Loading ...

Clearmind Medicine Announces Johns Hopkins Irb Approval to Advance Cmnd-100 Phase I/Ii Clinical Trial to the Next Parts

THOMSON REUTERS
·
May 26

NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM

Reuters
·
May 21

Clearmind Medicine Inc trading halted, news pending

TIPRANKS
·
May 21

Top Premarket Decliners

MT Newswires Live
·
May 19

Clearmind agrees to convert $600,000 notes into common shares at $0.3 each

Reuters
·
May 19

Clearmind Medicine announces 1-for-10 reverse share split

TIPRANKS
·
May 19

Clearmind Medicine to execute 1-for-10 reverse stock split May 21

Reuters
·
May 19

BRIEF-Clearmind Medicine Announces 1-For-10 Reverse Share Split

Reuters
·
May 19

Clearmind Medicine Announces 1-for-10 Reverse Share Split

THOMSON REUTERS
·
May 19

Clearmind Medicine to sell USD 600,000 convertible notes at 90% of face value

Reuters
·
May 19

Clearmind Medicine signs new research agreement with Yissum Research Development

TIPRANKS
·
May 18

Clearmind signs preclinical study of MEAI with tirzepatide in obese mice

Reuters
·
May 18

Clearmind Medicine Signs Agreement to Examine Meai in Combination and Sequencing With Tirzepatide Against Blockbuster Glp-1 Medications

THOMSON REUTERS
·
May 18

Clearmind Medicine CEO DR. Adi Zuloff-Shani Named Delegate to Federal Policy Summit on Psychedelic Medicine in Washington, D.c.

THOMSON REUTERS
·
May 15

Clearmind doses 2 more patients in CMND-100 alcohol use disorder trial cohort 4

Reuters
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants NOW Treated in Ongoing Phase I/Iia Trial of Cmnd-100 for Alcohol Use Disorder

THOMSON REUTERS
·
May 12

Clearmind Medicine Reaches Important Clinical Milestone: 20 Participants Now Treated in Ongoing Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder

GlobeNewswire
·
May 12

Clearmind Medicine to host “Inside MEAI” webinar on CMND-100 trial data

Reuters
·
May 11

Clearmind Medicine Announces “Inside Meai” Webinar Featuring New Insights From Cmnd-100 Psychedelic Clinical Trial

THOMSON REUTERS
·
May 11

BRIEF-Clearmind Medicine Announces Filing Of European Patent Application For Novel Psychedelic Compounds For The Treatment Of Ptsd

Reuters
·
May 05